Wall Street is positive on Phio Pharmaceuticals Corp (PHIO). On average, analysts give Phio Pharmaceuticals Corp a Strong Buy rating. The average price target is $6.5, which means analysts expect the stock to rise by 156.92% over the next twelve months.
That average ranking earns Phio Pharmaceuticals Corp an Analyst Rating of 80, which is better than 80% of stocks based on data compiled by InvestorsObserver.
Why are Analyst Ratings Important?
Analytical research by professionals can be extremely useful when making investment decisions in the stock market. Analysts are able to observe industries in detail and learn how geographical impacts can affect a company's balance sheet. This information allows investors to make decisions ahead of the curve.
Investors Observer combines the ratings from these analysts and proceeds to percentile rank them. This grants you the ability to compare stocks in a comprehensive fashion as oppossed to a standard buy/hold/sell rating.
What's Happening With Phio Pharmaceuticals Corp Stock Today?
Phio Pharmaceuticals Corp (PHIO) stock has fallen -11.23% while the S&P 500 is up 1.26% as of 11:36 AM on Wednesday, Aug 12. PHIO is down -$0.32 from the previous closing price of $2.85 on volume of 478,137 shares. Over the past year the S&P 500 has risen 15.36% while PHIO is down -86.43%. PHIO lost -$16.25 per share the over the last 12 months.